Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer

OBJECTIVE. To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC). PATIENTS AND METHODS. Postme...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Schwartzberg, Lee S., Franco, Sandra X., Florance, Allison, O'Rourke, Lisa, Maltzman, Julie, Johnston, Stephen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2010
Gaiak:
Academia–Pharma Intersect
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227947/
https://ncbi.nlm.nih.gov/pubmed/20156908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0240
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak